These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8341382)

  • 1. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
    Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
    Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
    Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
    Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clinical trial of regional anticoagulation for hemodialysis.
    Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
    ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
    Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
    Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
    Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
    J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
    Akizawa T
    Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
    Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
    Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
    Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
    Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
    Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adsorption of nafamostat mesilate by hemodialysis membranes.
    Inagaki O; Nishian Y; Iwaki R; Nakagawa K; Takamitsu Y; Fujita Y
    Artif Organs; 1992 Dec; 16(6):553-8. PubMed ID: 1482323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafamostat mesilate reduces blood loss during open heart surgery.
    Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
    Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
    Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
    ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
    Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
    Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac surgery in hemodialysis patients].
    Hoshino R; Okubo T; Kaneko K; Goko C
    Nihon Kyobu Geka Gakkai Zasshi; 1993 Jul; 41(7):1143-8. PubMed ID: 8376883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.
    Takahashi H; Muto S; Nakazawa E; Yanagiba S; Masunaga Y; Miyata Y; Tamba K; Kusano E; Matsuo M; Matsuo T; Asano Y
    Clin Nephrol; 2003 Jun; 59(6):458-62. PubMed ID: 12834179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
    Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
    Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S; Egi M; Kita H; Miyatake Y; Kubota K; Mizobuchi S
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.